Search

FDA Glucocorticoid Receptor Gene Expression Study

The FDA has posted a study concerning Glucocorticoid Receptor gene expression. This notice is for informational purposes and does not introduce new regulatory requirements.

FDA Acknowledgment Letter to J.M.W. Entertainment Group

The FDA issued an acknowledgment letter to The J.M.W. Entertainment Group, LLC, regarding a submission. This notice confirms receipt of documentation by the FDA's Center for Devices and Radiological Health (CDRH).

FDA Variance Application from Audio Source, Inc

The FDA has posted a variance application from Audio Source, Inc. This document is available for review on the Regs.gov platform. The application pertains to medical device regulations.

FDA Variance Amendment from J.M.W. Entertainment Group

The FDA has posted a variance amendment from J.M.W. Entertainment Group, LLC. The document was made available on March 16, 2026, via the Regs.gov portal. No further details on the amendment's content are provided.

FDA Complaint Document Posted

The FDA has posted a complaint document related to its regulatory activities. The document was made available on March 16, 2026, and was open for public comment. No specific details about the complaint's content or the nature of the comment period are provided.

FDA Document on Contraceptive Status Among Females 15-49

The Food and Drug Administration (FDA) has issued a document concerning contraceptive status among females aged 15-49. This notice provides information on the topic without introducing new regulatory requirements.

Hormonal Contraceptive Eligibility for Women at High HIV Risk

The FDA has issued draft guidance regarding the eligibility of hormonal contraceptives for women at high risk of HIV. This guidance aims to clarify recommendations and ensure appropriate access to contraceptive methods while considering HIV prevention strategies.

FDA Background Material on Contraceptive Use and HIV-1 Transmission Risk

The FDA has posted background material concerning contraceptive use and the risk of HIV-1 transmission. This notice provides scientific information relevant to public health discussions and regulatory considerations.

FDA Variance Application from J.M.W. Entertainment Group

The FDA has posted a variance application from The J.M.W. Entertainment Group, LLC. This document is available for review on the Regs.gov platform. No further details on the nature of the variance or its implications are provided in the notice.

FDA Progestins Classification and Pharmacology

The Food and Drug Administration (FDA) has published a document detailing the classification and pharmacology of progestins. This guidance provides information for manufacturers and pharmaceutical companies regarding these substances.